Abstract
Wastewater monitoring for infectious disease targets is increasingly used to better understand circulation of diseases. The present study validated hydrolysis-probe digital droplet (reverse-transcriptase (RT))-PCR assays for important enteric viruses (rotavirus, adenovirus group F, norovirus GI and GII, and enteroviruses), outbreak or emerging viruses (hepatitis A and West Nile virus), and an emerging drug resistant fungal pathogen (Candida auris). We used the assays to retrospectively measure concentrations of the targets in wastewater solids. Viral and fungal nucleic-acid concentrations were measured in two wastewater solids samples per week at two wastewater treatment plants in the San Francisco Bay Area of California, USA for 26 months. We detected all targets in wastewater solids with the exception of West Nile virus. At both wastewater treatment plants, human adenovirus group F was detected at the highest concentrations, followed by norovirus GII, enteroviruses, norovirus GI, and rotavirus at the lowest concentrations. Hepatitis A and C. auris were detected less consistently than the aforementioned viruses. Enterovirus D68 was detected in a limited time frame during fall 2022 at both sites. The measurements reported herein, and in some cases their seasonal trends, are consistent with previous reports of these targets in wastewater. These measurements represent some of the first quantitative measurements of these infectious disease targets in the solid fraction of wastewater. This study lays a foundation for the use of wastewater solids for the detection of specific infectious disease targets in wastewater monitoring programs aimed to better understand the spread of these diseases.
Competing Interest Statement
BW, BH, and DD are employees of Verily Life Sciences, LLC.
Funding Statement
The study was funded by a gift from the Sergey Brin Family Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
